Overview:
Olanzapine is structurally similar to clozapine, and is classified as a thienobenzodiazepine. Olanzapine has a higher affinity for 5-HT2 serotonin receptors than D2 dopamine receptors.
Like most atypical antipsychotics, compared to the older typical ones, olanzapine has a lower affinity for histamine, cholinergic muscarinic and alpha adrenergic receptors. The mode of action of olanzapine's antipsychotic activity is unknown. It may involve antagonism at serotonin receptors. Antagonism of dopamine receptors is associated with extrapyramidal effects such as tardive dyskinesia, and with therapeutic effects. Antagonizing H1 histamine receptors causes sedation and may cause weight gain, although antagonistic actions at 5-HT2C receptors have also been implicated in weight gain.
Zyprexa has been prescribed to nearly 20 million people in 84 countries since its approval in 1996. It was the first of a newer generation of antipsychotic medications (called atypical antipsychotics) approved for the long-term treatment of schizophrenia and acute bipolar mania.
Side Effects:
As with all neuroleptic drugs, olanzapine can cause tardive dyskinesia and rare, but life-threatening, neuroleptic malignant syndrome.
Other recognised side effects may include:
Aggressiveness
akathisia inability to remain still
dry mouth
dizziness
irritability
sedation
insomnia
urinary retention
orthostatic hypotension
weight gain (90% of users experience weight gain)
increased appetite
runny nose
low blood pressure
impaired judgment, thinking, and motor skills
impaired spatial orientation
impaired responses to senses
seizure
trouble swallowing
dental problems and discoloration of teeth
missed periods
problems with keeping body temperature regulated
apathy, lack of emotion
More Info:
Zyprexa Patient Information
Use Statistics
